 |
141 Diseases |  |
27 Trials |
|
27 Trials |  |
1501 News |  |
| «1234567891011» |
- || octreotide acetate / Generic mfg.
Trial primary completion date, Metastases: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - Oct 18, 2016
P2, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2016 --> Dec 2016
- | Oclaiz (octreotide subcutaneous depot) / Camurus
Trial completion, Enrollment change: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Oct 11, 2016
P2, N=12, Completed, Sponsor: Camurus AB
Trial primary completion date: Sep 2016 --> Dec 2016 Active, not recruiting --> Completed | N=24 --> 12
- Sandostatin LAR Depot (octreotide acetate) / Novartis
New P2 trial: Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients (clinicaltrials.gov) - Sep 27, 2016
P2, N=30, Enrolling by invitation, Sponsor: Danbury Hospital
- Sandostatin LAR Depot (octreotide acetate) / Novartis
New P2 trial: Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber (clinicaltrials.gov) - Aug 21, 2016
P2, N=15, Not yet recruiting, Sponsor: Radboud University
- ||| octreotide acetate / Generic mfg.
Trial initiation date, Metastases: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - Aug 9, 2016
P2, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=24 --> 12 Initiation date: May 2014 --> Dec 2014
- ||||| Lutathera (lutetium Lu 177 dotatate) / Novartis, octreotide acetate / Generic mfg.
Enrollment change: NETTER-1: A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (clinicaltrials.gov) - Jun 10, 2016
P3, N=230, Active, not recruiting, Sponsor: Advanced Accelerator Applications
Initiation date: May 2014 --> Dec 2014 N=359 --> 230
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - May 31, 2016
P2a, N=27, Recruiting, Sponsor: Ipsen
N=359 --> 230 Trial primary completion date: Feb 2017 --> Jun 2018
- capecitabine / Generic mfg.
Enrollment open: Lu-Ca-S: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - May 26, 2016
P2, N=176, Recruiting, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Trial primary completion date: Feb 2017 --> Jun 2018 Not yet recruiting --> Recruiting
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Trial primary completion date, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - May 13, 2016
P1, N=27, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Jul 2014
- |||| octreotide acetate / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - Apr 18, 2016
P2, N=140, Recruiting, Sponsor: Novartis
Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Jul 2014 Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> May 2014 | Trial primary completion date: Jun 2016 --> Sep 2016
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial primary completion date: ALADIN2: Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency (clinicaltrials.gov) - Apr 14, 2016
P3, N=98, Active, not recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> May 2014 | Trial primary completion date: Jun 2016 --> Sep 2016 Trial primary completion date: May 2016 --> Mar 2017
- | capecitabine / Generic mfg.
New P2 trial: Lu-Ca-S: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 13, 2016
P2, N=176, Not yet recruiting, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
- |||| octreotide acetate / Generic mfg.
Trial primary completion date, Metastases: Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 12, 2016
P3, N=270, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2016 --> Mar 2017 Trial primary completion date: Mar 2008 --> Oct 2005
- Oclaiz (octreotide subcutaneous depot) / Camurus
Trial primary completion date: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Mar 15, 2016
P2, N=24, Active, not recruiting, Sponsor: Camurus AB
Trial primary completion date: Mar 2008 --> Oct 2005 Trial primary completion date: Feb 2016 --> May 2016
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - Mar 1, 2016
P2a, N=27, Recruiting, Sponsor: Ipsen
Trial primary completion date: Feb 2016 --> May 2016 Trial primary completion date: Apr 2016 --> Feb 2017
- ||||| Lutathera (lutetium Lu 177 dotatate) / Novartis, octreotide acetate / Generic mfg.
Enrollment closed, Enrollment change: NETTER-1: A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (clinicaltrials.gov) - Feb 22, 2016
P3, N=359, Active, not recruiting, Sponsor: Advanced Accelerator Applications
Trial primary completion date: Apr 2016 --> Feb 2017 Recruiting --> Active, not recruiting | N=280 --> 359
- | Avastin (bevacizumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion: Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers (clinicaltrials.gov) - Feb 5, 2016
P2, N=43, Completed, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting | N=280 --> 359 Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Dec 9, 2015
P1, N=27, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=19 --> 27
- | Oclaiz (octreotide subcutaneous depot) / Camurus
Enrollment closed, Trial primary completion date: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Nov 27, 2015
P2, N=24, Active, not recruiting, Sponsor: Camurus AB
N=19 --> 27 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Feb 2016
- | octreotide acetate / Generic mfg.
Trial completion: Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer (clinicaltrials.gov) - Nov 16, 2015
P3, N=233, Completed, Sponsor: Radiation Therapy Oncology Group
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Feb 2016 Active, not recruiting --> Completed
- || Sandostatin LAR Depot (octreotide acetate) / Novartis
New P3 trial: The effectiveness of the drug octreotide to anemia in patients with small bowel bleeding due to vascualr malformations. (EUDRACT) - Oct 6, 2015
P3, N=62, Ongoing, Sponsor: Radboud University Medical Center
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment open, Trial initiation date, Trial primary completion date: OCEAN: Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias (clinicaltrials.gov) - Sep 24, 2015
P2/3, N=62, Recruiting, Sponsor: Radboud University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Jun 2017 --> Nov 2017
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion, Trial primary completion date: ELATE: Everolimus and LongActing Octreotide Trial in Polycystic Livers (clinicaltrials.gov) - Jun 29, 2015
P2, N=44, Completed, Sponsor: Radboud University
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Jun 2017 --> Nov 2017 Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Jul 2012
- Oclaiz (octreotide subcutaneous depot) / Camurus
Trial primary completion date: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Jun 11, 2015
P2, N=24, Recruiting, Sponsor: Camurus AB
Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Jul 2012 Trial primary completion date: Apr 2015 --> Oct 2015
- ||| Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment change, Trial primary completion date: Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. (clinicaltrials.gov) - Jun 11, 2015
P4, N=52, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2015 --> Oct 2015 N=31 --> 52 | Trial primary completion date: Jun 2022 --> Sep 2022
- | motesanib (AMG 706) / Takeda
Trial completion, Trial primary completion date: AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors (clinicaltrials.gov) - Jun 4, 2015
P2, N=46, Completed, Sponsor: Eastern Cooperative Oncology Group
N=31 --> 52 | Trial primary completion date: Jun 2022 --> Sep 2022 Active, not recruiting --> Completed | Trial primary completion date: Nov 2012 --> Oct 2014
- cisplatin / Generic mfg., irinotecan / Generic mfg.
Trial completion, Metastases: IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC (clinicaltrials.gov) - May 19, 2015
P2, N=40, Completed, Sponsor: Peking University
Active, not recruiting --> Completed | Trial primary completion date: Nov 2012 --> Oct 2014 Recruiting --> Completed
- Sandostatin LAR Depot (octreotide acetate) / Novartis
New P4 trial, Surgery: Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues (clinicaltrials.gov) - Apr 30, 2015
P4, N=1, Recruiting, Sponsor: Asan Medical Center
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion, Trial primary completion date: Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD) (clinicaltrials.gov) - Apr 29, 2015
P1, N=10, Completed, Sponsor: Virginia Commonwealth University
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Oct 2014
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - Apr 25, 2015
P2a, N=27, Recruiting, Sponsor: Ipsen
Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Oct 2014 Not yet recruiting --> Recruiting
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial primary completion date: ALADIN2: Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency (clinicaltrials.gov) - Apr 14, 2015
P3, N=98, Active, not recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Not yet recruiting --> Recruiting Trial primary completion date: May 2015 --> May 2016
- | octreotide acetate / Generic mfg.
New P2 trial, Metastases: Octreotide LAR as Maintenance Treatment for Patients With NEC (clinicaltrials.gov) - Apr 7, 2015
P2, N=92, Not yet recruiting, Sponsor: Peking University
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P2a trial, New P3 trial: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - Mar 24, 2015
P2a, N=27, Not yet recruiting, Sponsor: Ipsen
- || Sandostatin LAR Depot (octreotide acetate) / Novartis
New P2/3 trial: OCEAN: Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias (clinicaltrials.gov) - Mar 10, 2015
P2/3, N=62, Not yet recruiting, Sponsor: Radboud University
- |||| Lutathera (lutetium Lu 177 dotatate) / Novartis, octreotide acetate / Generic mfg.
Trial primary completion date: NETTER-1: A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (clinicaltrials.gov) - Mar 7, 2015
P3, N=280, Recruiting, Sponsor: Advanced Accelerator Applications
Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: Dec 2014 --> Jun 2015
- | Oclaiz (octreotide subcutaneous depot) / Camurus
Enrollment open: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Jan 26, 2015
P2, N=24, Recruiting, Sponsor: Camurus AB
Trial primary completion date: Dec 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment change, Trial termination: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome (clinicaltrials.gov) - Jan 12, 2015
P2, N=2, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting N=20 --> 2 | Completed --> Terminated; Slow accrual
- octreotide acetate / Generic mfg.
New P2 trial: CEVOREM: Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas (clinicaltrials.gov) - Jan 7, 2015
P2, N=20, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
- Inlyta (axitinib) / Pfizer, octreotide acetate / Generic mfg.
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas (clinicaltrials.gov) - Dec 9, 2014
P2, N=80, Active, not recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
N=20 --> 2 | Completed --> Terminated; Slow accrual Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jul 2015
- ||| octreotide acetate / Generic mfg.
Enrollment closed: Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target (clinicaltrials.gov) - Dec 9, 2014
P4, N=75, Active, not recruiting, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jul 2015 Recruiting --> Active, not recruiting
- prednisone / Generic mfg., docetaxel / Generic mfg., cabazitaxel / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel (clinicaltrials.gov) - Nov 24, 2014
P2, N=9, Terminated, Sponsor: University of Southern California
Recruiting --> Active, not recruiting N=50 --> 9 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Oct 2014; lack of funding
- | Oclaiz (octreotide subcutaneous depot) / Camurus
New P2 trial: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (clinicaltrials.gov) - Nov 24, 2014
P2, N=24, Not yet recruiting, Sponsor: Camurus AB
- octreotide acetate / Generic mfg.
New P2 trial, Combination therapy, Metastases: MetNET1: Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs (clinicaltrials.gov) - Nov 19, 2014
P2, N=43, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- ||||| octreotide acetate / Generic mfg.
New P2 trial, Metastases: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - Nov 19, 2014
P2, N=140, Not yet recruiting, Sponsor: GlaxoSmithKline
- ||||| Signifor LAR (pasireotide long acting release) / Recordati, Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment change: Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly (clinicaltrials.gov) - Nov 18, 2014
P3, N=358, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=50 --> 9 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Oct 2014; lack of funding N=533 --> 358
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion, Enrollment change, Trial primary completion date: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome (clinicaltrials.gov) - Oct 28, 2014
P2, N=20, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=533 --> 358 Active, not recruiting --> Completed | N=30 --> 20 | Trial primary completion date: Apr 2018 --> Aug 2014
- |||| Signifor LAR (pasireotide long acting release) / Recordati, Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial primary completion date: PAOLA: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (clinicaltrials.gov) - Oct 23, 2014
P3, N=190, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=30 --> 20 | Trial primary completion date: Apr 2018 --> Aug 2014 Trial primary completion date: Dec 2015 --> Jan 2013
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment closed: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome (clinicaltrials.gov) - Sep 28, 2014
P2, N=30, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Dec 2015 --> Jan 2013 Recruiting --> Active, not recruiting
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment closed: ALADIN2: Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency (clinicaltrials.gov) - Sep 19, 2014
P3, N=98, Active, not recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers (clinicaltrials.gov) - Sep 12, 2014
P2, N=43, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Feb 2015